Stephen B. Porter

2.9k citations
54 papers · 2.2k · h-index 24

Impact in

  • Molecular Medicine top 0.5%
    • Antibiotic Resistance in Bacteria
  • Endocrinology top 0.5%
    • Escherichia coli research studies
    • Enterobacteriaceae and Cronobacter Research

Papers in

Co-authors
James R. Johnson (39 shared papers)Brian Johnston (26 shared papers)Bruce R. Blazar (7 shared papers)Wayne R. Godfrey (5 shared papers)Paul Thuras (21 shared papers)Carl H. June (5 shared papers)Bruce L. Levine (4 shared papers)Connie Clabots (18 shared papers)
Journals
Antimicrobial Agents and Chemotherapy (10 papers)Blood (6 papers)Open Forum Infectious Diseases (6 papers)The Journal of Infectious Diseases (3 papers)Clinical Infectious Diseases (3 papers)
Partner nations
United StatesCanadaNew Zealand

In The Last Decade

Stephen B. Porter

54 papers receiving 2.2k citations

Peers

Stephen B. Porter
Comparison fields: 5 of 92
  • Molecular Medicine 796
  • Endocrinology 609
  • Applied Microbiology and Biotechnology 57
  • Immunology 594
  • Clinical Biochemistry 107
Replace Seiichi Inamura with:
Seiichi Inamura Japan
Hong Du China
Julie Segre United States
Yukiko Nagano Japan
Jui‐Fen Lai Taiwan
Wenjuan Yin China
Mark Pelletier United States
Bart W. Bardoel Netherlands
J. R. W. Govan United Kingdom
Yutaka Tokue Japan
Stephen B. Porter relative to Seiichi Inamura Japan Seiichi Inamura's profile →
Citations per field
00.5×2×4×6.3×
Seiichi Inamura · 1×
Citations per year

Countries citing papers authored by Stephen B. Porter

Since Specialization
Citations

This map shows the geographic impact of Stephen B. Porter's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Stephen B. Porter with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Stephen B. Porter more than expected).

Fields of papers citing papers by Stephen B. Porter

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Stephen B. Porter. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Stephen B. Porter. The network helps show where Stephen B. Porter may publish in the future.

Co-authors

The 25 scholars most cited alongside Stephen B. Porter, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Stephen B. Porter Line = papers co-authored together Stephen B. Porter links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 54 papers — load more, or switch the sort, to bring in the rest.

#Work
1
In vitro–expanded human CD4+CD25+ T-regulatory cells can markedly inhibit allogeneic dendritic cell–stimulated MLR cultures
Blood ·Wayne R. Godfrey, Ying G. Ge, Darrin J. Spoden, Bruce L. Levine, Carl H. June, Bruce R. Blazar, Stephen B. Porter
2004237
2
Cord blood CD4+CD25+-derived T regulatory cell lines express FoxP3 protein and manifest potent suppressor function
Blood ·Wayne R. Godfrey, Darrin J. Spoden, Ying G. Ge, Seth Baker, Baoling Liu, Bruce L. Levine, Carl H. June, Bruce R. Blazar, Stephen B. Porter
2004237
3
Umbilical cord blood regulatory T-cell expansion and functional effects of tumor necrosis factor receptor family members OX40 and 4-1BB expressed on artificial antigen-presenting cells
Blood ·Keli L. Hippen, Paul Harker‐Murray, Stephen B. Porter, Sarah C. Merkel, Aryel Londer, Dawn K. Taylor, Megan Bina, Angela Panoskaltsis‐Mortari, Pablo Rubinstein, Nico van Rooijen, Tatiana N. Golovina, Megan M. Suhoski, Jeffrey S. Miller, John E. Wagner, Carl H. June, James L. Riley, Bruce R. Blazar
2008120
4
CD4+CD25+ regulatory T-cell lines from human cord blood have functional and molecular properties of T-cell anergy
Blood ·Lequn Li, Wayne R. Godfrey, Stephen B. Porter, Ying G. Ge, Carle H. June, Bruce R. Blazar, Vassiliki A. Boussiotis
2005117
5
Escherichia coliSequence Type 131 Is a Dominant, Antimicrobial-Resistant Clonal Group Associated with Healthcare and Elderly Hosts
Infection Control and Hospital Epidemiology ·Ritu Banerjee, Brian Johnston, Christine M. Lohse, Stephen B. Porter, Connie Clabots, James R. Johnson
2013111
6
IntermingledKlebsiella pneumoniaePopulations Between Retail Meats and Human Urinary Tract Infections
Clinical Infectious Diseases ·Gregg S. Davis, Kara Waits, Lora Nordstrom, Brett Weaver, Maliha Aziz, Lori Gauld, Heidi Grande, Rick Bigler, Joseph Horwinski, Stephen B. Porter, Marc Stegger, James R. Johnson, Cindy M. Liu, Lance B. Price
2015105
7
Virulence of Escherichia coli Clinical Isolates in a Murine Sepsis Model in Relation to Sequence Type ST131 Status, Fluoroquinolone Resistance, and Virulence Genotype
Infection and Immunity ·James R. Johnson, Stephen B. Porter, George G. Zhanel, Michael A. Kuskowski, Érick Denamur
201299
8
Molecular Epidemiology of Escherichia coli Sequence Type 131 and Its H30 and H30-Rx Subclones among Extended-Spectrum-β-Lactamase-Positive and -Negative E. coli Clinical Isolates from the Chicago Region, 2007 to 2010
Antimicrobial Agents and Chemotherapy ·Ritu Banerjee, Ari Robicsek, Michael A. Kuskowski, Stephen B. Porter, Brian Johnston, Evgeni V. Sokurenko, Veronika Tchesnokova, Lance B. Price, James R. Johnson
201397
9
Phenotypic analysis of Paf1/RNA polymerase II complex mutations reveals connections to cell cycle regulation, protein synthesis, and lipid and nucleic acid metabolism
Molecular Genetics and Genomics ·Joachim Betz, Mei‐Ping Chang, Tracy Washburn, Stephen B. Porter, Christopher G. Mueller, Judith A. Jaehning
200293
10
Host Characteristics and Bacterial Traits Predict Experimental Virulence for Escherichia coli Bloodstream Isolates From Patients With Urosepsis
Open Forum Infectious Diseases ·James R. Johnson, Stephen B. Porter, Brian Johnston, Michael A. Kuskowski, Rachel R. Spurbeck, Harry L. T. Mobley, Deborah A. Williamson
201582
11
The Pandemic H30 Subclone of Sequence Type 131 (ST131) as the Leading Cause of Multidrug-Resistant Escherichia coli Infections in the United States (2011–2012)
Open Forum Infectious Diseases ·James R. Johnson, Stephen B. Porter, Paul Thuras, Mariana Castanheira
201764
12
Rapid Emergence, Subsidence, and Molecular Detection of Escherichia coli Sequence Type 1193- fimH64 , a New Disseminated Multidrug-Resistant Commensal and Extraintestinal Pathogen
Journal of Clinical Microbiology ·James R. Johnson, Brian Johnston, Stephen B. Porter, Connie Clabots, Tricia Bender, Paul Thuras, Darren J. Trott, Rowland N. Cobbold, Joanne L. Mollinger, Patricia Ferrieri, Sarah M. Drawz, Ritu Banerjee
201955
13
Household Clustering of Escherichia coli Sequence Type 131 Clinical and Fecal Isolates According to Whole Genome Sequence Analysis
Open Forum Infectious Diseases ·James R. Johnson, Gregg S. Davis, Connie Clabots, Brian Johnston, Stephen B. Porter, Chitrita DebRoy, William F. Pomputius, Peter T. Ender, Michael Cooperstock, Billie C. S. Slater, Ritu Banerjee, Sybille A. Miller, Dagmara Kisiela, Evgeni V. Sokurenko, Maliha Aziz, Lance B. Price
201653
14
Epidemic Emergence in the United States of Escherichia coli Sequence Type 131- H 30 (ST131- H 30), 2000 to 2009
Antimicrobial Agents and Chemotherapy ·James R. Johnson, Stephen B. Porter, Paul Thuras, Mariana Castanheira
201748
15
Clinical and Microbiological Determinants of Infection After Transrectal Prostate Biopsy
Clinical Infectious Diseases ·Michael A. Liss, James R. Johnson, Stephen B. Porter, Brian Johnston, Connie Clabots, Kyle Gillis, Unwanaobong Nseyo, Marc Holden, Kyoko Sakamoto, Joshua Fierer
201447
16
Activity of Cefiderocol, Ceftazidime-Avibactam, and Eravacycline against Carbapenem-Resistant Escherichia coli Isolates from the United States and International Sites in Relation to Clonal Background, Resistance Genes, Coresistance, and Region
Antimicrobial Agents and Chemotherapy ·Brian Johnston, Paul Thuras, Stephen B. Porter, Melissa Anacker, Brittany VonBank, Paula Snippes Vagnone, Medora Witwer, Mariana Castanheira, James R. Johnson
202041
17
Mutational Analysis of the Ras Converting Enzyme Reveals a Requirement for Glutamate and Histidine Residues
Journal of Biological Chemistry ·Lisa J. Plummer, Emily R. Hildebrandt, Stephen B. Porter, Victoria A. Rogers, D. Jay McCracken, Walter K. Schmidt
200539
18
Extraintestinal Pathogenic and Antimicrobial-Resistant Escherichia coli, Including Sequence Type 131 (ST131), from Retail Chicken Breasts in the United States in 2013
Applied and Environmental Microbiology ·James R. Johnson, Stephen B. Porter, Brian Johnston, Paul Thuras, Sarah A. Clock, Michael Crupain, Urvashi Rangan
201738
19
Extensive Household Outbreak of Urinary Tract Infection and Intestinal Colonization due to Extended-Spectrum β-Lactamase–Producing Escherichia coli Sequence Type 131
Clinical Infectious Diseases ·Theresa Madigan, James R. Johnson, Connie Clabots, Brian Johnston, Stephen B. Porter, Billie C. S. Slater, Ritu Banerjee
201538
20
Accessory Traits and Phylogenetic Background Predict Escherichia coli Extraintestinal Virulence Better Than Does Ecological Source
The Journal of Infectious Diseases ·James R. Johnson, Brian Johnston, Stephen B. Porter, Paul Thuras, Maliha Aziz, Lance B. Price
201838

About Stephen B. Porter

Stephen B. Porter is a scholar working on Molecular Medicine, Endocrinology, Epidemiology, Immunology and Molecular Biology, having authored 54 papers that have together received 2.2k indexed citations. Recurring topics across this work include Antibiotic Resistance in Bacteria (25 papers), Escherichia coli research studies (24 papers), T-cell and B-cell Immunology (7 papers), Urinary Tract Infections Management (7 papers), Immune Cell Function and Interaction (7 papers), Antibiotics Pharmacokinetics and Efficacy (6 papers), Immunotherapy and Immune Responses (6 papers) and Salmonella and Campylobacter epidemiology (4 papers). The work is most often cited by research in Molecular Medicine (796 citations), Endocrinology (609 citations), Applied Microbiology and Biotechnology (57 citations), Immunology (594 citations) and Clinical Biochemistry (107 citations). Stephen B. Porter has collaborated with scholars based in United States, Canada and New Zealand. Frequent co-authors include James R. Johnson, Brian Johnston, Bruce R. Blazar, Wayne R. Godfrey, Paul Thuras, Carl H. June, Bruce L. Levine, Connie Clabots, Michael A. Kuskowski and Ritu Banerjee. Their work appears in journals such as Antimicrobial Agents and Chemotherapy, Blood, Open Forum Infectious Diseases, The Journal of Infectious Diseases and Clinical Infectious Diseases.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Seiichi InamuraBreakdown of academic impact, for papers by Hong DuBreakdown of academic impact, for papers by Julie SegreBreakdown of academic impact, for papers by Yukiko NaganoBreakdown of academic impact, for papers by Jui‐Fen LaiBreakdown of academic impact, for papers by Wenjuan YinBreakdown of academic impact, for papers by Mark PelletierBreakdown of academic impact, for papers by Bart W. BardoelBreakdown of academic impact, for papers by J. R. W. GovanBreakdown of academic impact, for papers by Yutaka Tokue